Related Experiment Videos
An update on cardiac enzymes
1Bugher Foundation Center for Molecular Biology, Baylor College of Medicine, Houston, Texas.
Insights
Plasma creatine kinase-MB (CK-MB) assays are highly accurate for diagnosing acute myocardial infarction (MI). However, clinicians should consider noncardiac sources or assay interference when CK-MB results conflict with the clinical picture.
Area of Science:
- Biochemistry
- Clinical Diagnostics
- Cardiology
Background:
- Accurate diagnosis of acute myocardial infarction (MI) is critical for timely therapeutic interventions.
- Current diagnostic methods rely on biochemical markers, with creatine kinase-MB (CK-MB) being a key indicator.
- Potential for elevated CK-MB in non-MI cases necessitates careful interpretation.
Purpose of the Study:
- To evaluate the diagnostic accuracy of plasma total and MB CK concentration for acute MI.
- To explore the utility of quantitative MB CK assays in estimating infarct size.
- To highlight the importance of CK-MB subforms in early MI diagnosis and reperfusion assessment.
Main Methods:
- Determination of plasma total and MB CK concentrations.
- Analysis of CK-MB subforms for early diagnostic potential.
- Correlation of biochemical findings with clinical settings.
Main Results:
- Plasma total and MB CK assays offer superior accuracy for acute MI diagnosis compared to other methods.
- Elevated MB CK can occur without acute MI due to assay-dependent or noncardiac factors.
- Quantitative MB CK assays accurately estimate infarct size.
- New CK-MB subforms show promise for early MI diagnosis and noninvasive reperfusion assessment.
Conclusions:
- Plasma CK-MB measurement is a precise tool for diagnosing acute MI and assessing infarct size.
- Clinicians must consider clinical context to differentiate true MI from spurious or noncardiac CK-MB elevations.
- Emerging CK-MB subforms represent a significant advancement in early acute MI detection and reperfusion monitoring.
Abstract:
Determination of plasma total and MB CK concentration provides accuracy superior to any other currently available method for the diagnosis of acute MI. Nevertheless, elevation of MB CK is occasionally detected in the absence of acute MI for several reasons, some of them assay-dependent; consequently, the clinician should suspect a noncardiac source of MB CK or a spurious result if assay determinations are discordant with the clinical setting. In addition to providing precise diagnosis of acute MI, quantitative MB CK assays can also be used to obtain an accurate estimate of infarct size. In recent years, accuracy in the diagnosis of acute MI has assumed even greater importance, since the choice and timing of a variety of diagnostic and therapeutic options following coronary care unit admission hinge on whether infarction has occurred. Furthermore, the advent of thrombolytic therapy of acute MI has emphasized the need for more sensitive biochemical markers of necrosis in the first hours; the newly discovered subforms of MM and MB CK show promise as a means of proving an early diagnosis of acute MI and also as a means of assessing reperfusion noninvasively.